Pfizer Czech Republic

Profit Statement 2015 2016 2017
Sales CZK mil 3,122 3,243 3,586
Gross Profit CZK mil 311 366 445
EBITDA CZK mil 110 120 156
EBIT CZK mil 98.2 98.0 132
Financing Cost CZK mil 6.38 4.31 6.17
Pre-Tax Profit CZK mil 91.9 93.7 126
Net Profit CZK mil 75.4 73.4 103
Balance Sheet 2015 2016 2017
Total Assets CZK mil 1,937 2,051 2,549
Non-Current Assets CZK mil 197 195 312
Current Assets CZK mil 1,737 1,853 2,234
Working Capital CZK mil 1,107 1,234 1,617
Shareholders' Equity CZK mil 1,180 1,253 1,355
Liabilities CZK mil 757 798 1,194
Total Debt CZK mil 0 0 338
Net Debt CZK mil -4.12 -5.68 329
Ratios 2015 2016 2017
ROE % 5.24 6.03 7.86
ROCE % 7.83 5.37 6.11
Gross Margin % 9.96 11.3 12.4
EBITDA Margin % 3.54 3.69 4.36
EBIT Margin % 3.15 3.02 3.68
Net Margin % 2.41 2.26 2.86
Net Debt/EBITDA -0.037 -0.047 2.10
Net Debt/Equity % -0.350 -0.453 24.2
Cost of Financing % ... ... 3.65
Cash Flow 2015 2016 2017
Total Cash From Operations CZK mil ... 26.2 -700
Total Cash From Investing CZK mil ... -24.6 703
Total Cash From Financing CZK mil ... 0 0
Net Change In Cash CZK mil ... 1.55 3.21
Cash Conversion Cycle days 131 141 166
Cash Earnings CZK mil 87.5 95.0 127
Free Cash Flow CZK mil ... 1.55 3.21

Get all company financials in excel:

Download Sample   $19.99

summary Unit 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
income statement                                
Sales CZK mil                   6,807 3,118 5,407 4,947 3,122    
Gross Profit CZK mil                   755 287 502 475 311    
EBIT CZK mil                   303 63.4 170 170 98.2    
Net Profit CZK mil                   231 48.1 144 134 75.4    
ROE %                   25.2 4.63 11.1 8.21 5.24    
EBIT Margin %                   4.45 2.03 3.15 3.44 3.15    
Net Margin %                   3.40 1.54 2.67 2.70 2.41    
Employees                   253 203 183 170 121    
balance sheet                                
Total Assets CZK mil                   2,885 2,530 2,812 2,922 1,937    
Non-Current Assets CZK mil                   16.5 9.46 7.30 99.1 197    
Current Assets CZK mil                   2,866 2,518 2,798 2,818 1,737    
Shareholders' Equity CZK mil                   1,034 1,043 1,562 1,696 1,180    
Liabilities CZK mil                   1,851 1,487 1,249 1,226 757    
Non-Current Liabilities CZK mil                   0.438 0.438 0 0 0    
Current Liabilities CZK mil                   1,835 1,474 1,226 1,212 742    
Net Debt/EBITDA                   2.16 -1.32 -0.141 -1.65 -0.037    
Net Debt/Equity %                   66.1 -8.43 -1.56 -16.8 -0.350    
Cost of Financing % ... ...             ... 4.09 0.877 ... ... ... ...  
cash flow                                
Total Cash From Operations CZK mil             ... ... ... ... ... ... ... ...    
Total Cash From Investing CZK mil             ... ... ... ... ... ... ... ...    
Total Cash From Financing CZK mil             ... ... ... ... ... ... ... ...    
Net Change In Cash CZK mil             ... ... ... ... ... ... ... ...    
income statement Unit 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
income statement                                
Sales CZK mil                   6,807 3,118 5,407 4,947 3,122    
Cost of Goods & Services CZK mil                   6,051 2,831 4,905 4,472 2,811    
Gross Profit CZK mil                   755 287 502 475 311    
Staff Cost CZK mil                   389 127 266 271 175    
Other Cost CZK mil                   50.5 93.9 63.8 31.9 25.7    
EBITDA CZK mil                   316 66.4 173 172 110    
Depreciation CZK mil                   13.5 2.99 2.56 2.12 12.2    
EBIT CZK mil                   303 63.4 170 170 98.2    
Financing Cost CZK mil                   17.5 3.75 0.699 4.58 6.38    
Extraordinary Cost CZK mil                   -0.007 0.002 -8.21 0.063 0    
Pre-Tax Profit CZK mil                   285 59.6 178 165 91.9    
Tax CZK mil                   53.8 11.6 33.5 31.6 16.5    
Minorities CZK mil                   0 0 0 0 0    
Net Profit CZK mil                   231 48.1 144 134 75.4    
growth rates                                
Total Revenue Growth % ...                 4.32 -54.2 73.4 -8.51 -36.9    
Operating Cost Growth % ...                 -17.5 -49.8 49.5 -8.06 -33.8    
EBITDA Growth % ...                 93.1 -79.0 160 -0.368 -35.9    
EBIT Growth % ...                 114 -79.1 169 -0.115 -42.2    
Pre-Tax Profit Growth % ...                 132 -79.1 198 -6.94 -44.5    
Net Profit Growth % ...                 137 -79.2 200 -7.25 -43.7    
ratios                                
ROE %                   25.2 4.63 11.1 8.21 5.24    
ROCE % ...                 13.9 4.56 18.1 16.1 7.83    
Gross Margin %                   11.1 9.20 9.29 9.61 9.96    
EBITDA Margin %                   4.64 2.13 3.20 3.48 3.54    
EBIT Margin %                   4.45 2.03 3.15 3.44 3.15    
Net Margin %                   3.40 1.54 2.67 2.70 2.41    
Cost of Financing % ... ...             ... 4.09 0.877 ... ... ... ...  
Net Debt/EBITDA                   2.16 -1.32 -0.141 -1.65 -0.037    
balance sheet Unit 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
balance sheet                                
Non-Current Assets CZK mil                   16.5 9.46 7.30 99.1 197    
Property, Plant & Equipment CZK mil                   16.3 9.44 7.30 5.16 3.21    
Intangible Assets CZK mil                   0.181 0.026 0 93.9 194    
Current Assets CZK mil                   2,866 2,518 2,798 2,818 1,737    
Inventories CZK mil                   959 933 1,095 813 716    
Receivables CZK mil                   1,305 900 973 733 1,007    
Cash & Cash Equivalents CZK mil                   172 87.9 24.3 284 4.12    
Total Assets CZK mil                   2,885 2,530 2,812 2,922 1,937    
Shareholders' Equity CZK mil                   1,034 1,043 1,562 1,696 1,180    
Of Which Minority Interest CZK mil                   0 0 0 0 0    
Liabilities CZK mil                   1,851 1,487 1,249 1,226 757    
Non-Current Liabilities CZK mil                   0.438 0.438 0 0 0    
Long-Term Debt CZK mil                   0 0 0 0 0    
Deferred Tax Liabilities CZK mil                   0 0 0 0 0    
Current Liabilities CZK mil                   1,835 1,474 1,226 1,212 742    
Short-Term Debt CZK mil                   856 0 0 0 0    
Trade Payables CZK mil                   734 1,280 1,039 1,023 616    
Provisions CZK mil                   16.2 12.9 23.3 13.5 15.0    
Equity And Liabilities CZK mil                   2,885 2,530 2,812 2,922 1,937    
growth rates                                
Total Asset Growth % ...                 -3.91 -12.3 11.1 3.91 -33.7    
Shareholders' Equity Growth % ...                 28.8 0.865 49.8 8.56 -30.5    
Net Debt Growth % ...                 -703 -113 -72.3 1,069 -98.5    
Total Debt Growth % ... ... ...       ...   ... ... -100 ... ... ... ... ...
ratios                                
Total Debt CZK mil                   856 0 0 0 0    
Net Debt CZK mil                   684 -87.9 -24.3 -284 -4.12    
Working Capital CZK mil                   1,530 552 1,028 523 1,107    
Capital Employed CZK mil                   1,546 561 1,035 622 1,304    
Net Debt/Equity %                   66.1 -8.43 -1.56 -16.8 -0.350    
Cost of Financing % ... ...             ... 4.09 0.877 ... ... ... ...  
cash flow Unit 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
cash flow                                
Net Profit CZK mil                   231 48.1 144 134 75.4    
Depreciation CZK mil                   13.5 2.99 2.56 2.12 12.2    
Non-Cash Items CZK mil ...           ... ... ... ... ... ... ... ...    
Change in Working Capital CZK mil ...           ... ... ... ... ... ... ... ...    
Total Cash From Operations CZK mil             ... ... ... ... ... ... ... ...    
Capital Expenditures CZK mil             ... ... ... ... ... ... ... ...    
Other Investments CZK mil             ... ... ... ... ... ... ... ...    
Total Cash From Investing CZK mil             ... ... ... ... ... ... ... ...    
Issuance Of Shares CZK mil ... ... ... ... ... ... ... ... ... ... ... ... ... ...    
Issuance Of Debt CZK mil ...           ... ... ... ... ... ... ... ...    
Total Cash From Financing CZK mil             ... ... ... ... ... ... ... ...    
Net Change In Cash CZK mil             ... ... ... ... ... ... ... ...    
ratios                                
Days Sales Outstanding days                   70.0 105 65.7 54.1 118    
Days Sales Of Inventory days                   57.8 120 81.5 66.3 92.9    
Days Payable Outstanding days                   44.3 165 77.4 83.5 80.0    
Cash Conversion Cycle days                   83.6 60.5 69.8 36.9 131    
Cash Earnings CZK mil                   245 51.0 147 136 87.5    
Free Cash Flow CZK mil             ... ... ... ... ... ... ... ...    
other data Unit 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
other data                                
ROA %                   7.86 1.77 5.40 4.67 3.10    
Gross Margin %                   11.1 9.20 9.29 9.61 9.96    
Employees                   253 203 183 170 121    
Cost Per Employee USD per month                   7,241 2,655 6,187 6,218 5,044    
Cost Per Employee (Local Currency) CZK per month                   128,064 51,930 121,053 132,894 120,395    
Staff Cost (As % Of Total Cost) %                   5.98 4.14 5.08 5.68 5.78    
Effective Tax Rate %                   18.9 19.4 18.9 19.1 18.0    
Domestic Sales CZK mil                   3,372 1,524 2,727 2,528 1,254    
Capital Expenditures (As % of Sales) %             ... ... ... ... ... ... ... ...    
Revenues From Abroad CZK mil                   3,436 1,594 2,680 2,418 1,868    
Revenues From Abroad (As % Of Total) %                   50.5 51.1 49.6 48.9 59.8    
Sales of Goods CZK mil                   3,395 1,502 2,710 2,524 2,824    
Sales Of Services CZK mil                   3,413 1,616 2,697 2,422 298    

Get all company financials in excel:

Download Sample   $19.99

Pfizer Czech Republic is a Czech Republic-based subsidiary of the multinational pharmaceutical corporation Pfizer. Pfizer, Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin for neuropathic pain/fibromyalgia); Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil, for erectile dysfunction); and Celebrex/Celebra (celecoxib), an anti-inflammatory drug. Pfizer was founded by cousins Charles Pfizer and Charles Erhart in New York City in 1849 as a manufacturer of fine chemicals

Pfizer Czech Republic Logo